Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B, BaxHTN Investigators
- DOI
- 10.1056/NEJMoa2507109
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-22
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/3bf8085c-3ece-4c98-aae6-46fde7c90682 is authoritative.
How this rating was calculated
- StatisticsImpossible or misreported statistic ×2−2★
- IntegrityIntegrity concern ×2−1★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- StatisticsPrinted percentage does not match its own count (capped) ×3−0.25★
- ReportingData & code availability partially met−0.25★
A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.
- The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 21 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
- 01Printed percentage does not match its own countdemonstrable
19.1% does not match the reported count 49/264
“49 (19.1%)”
Safety - 02Printed percentage does not match its own countdemonstrable
22.8% does not match the reported count 59/266
“59 (22.8%)”
Safety - 03Efficacy rests on an unvalidated surrogate endpoint
The primary endpoint is change in seated systolic blood pressure (SBP), a surrogate for cardiovascular outcomes. The paper does not demonstrate target engagement at the tested doses (e.g., PK/PD or dose-exposure relationship) nor cite validated evidence linking SBP reduction to clinical outcomes in this context. Although SBP is a well-established surrogate for cardiovascular risk, the manuscript does not explicitly provide such validation or target engagement data.
“The primary efficacy end point was the change in seated-SBP, from baseline to week 12, assessed for each baxdrostat group versus placebo.”
- 04Printed percentage does not match its own count
7% does not match the reported count 18/264
“18 (7.0%)”
Safety - 05Printed percentage does not match its own count
12.6% does not match the reported count 33/264
“12.6%”
Safety - 06Printed percentage does not match its own count
15.6% does not match the reported count 41/266
“15.6%”
Safety
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted phase 3 randomized controlled trial with rigorous design, clear reporting of ethics, demographics, and statistical methods. The main weakness is the absence of a data availability statement, which is a notable reporting gap for a clinical trial. Minor copyedit issues and a small discrepancy in the number randomized (794 vs 796) are also present.
Both reviewers independently scored all eight dimensions and agreed on every status. The study type is interventional (phase 3 RCT). The statistics verification component recomputed a subset of tests (12 total, 7 consistent, 5 inconsistent with no decision errors), but this does not affect the pass status; the unverified tests remain unconfirmed. The integrity check flagged a minor discrepancy in the number randomized (794 vs 796) and a low-severity internal contradiction that is not a true contradiction.
Numerical inconsistencies
3 findings · worst criticalValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
- Printed percentage does not match its own countRecomputed
- Internal contradictions in the reported numbersAssessed
Recomputed 7 tests: 7 consistent, 0 inconsistent; 7 via agent-written checks. 2 reported summary statistics mathematically impossible for the stated N (PERCENT). 3 printed percentages that do not match their own count.
- PERCENT19.1% does not match the reported count 49/264
“49 (19.1%)”
Safety - PERCENT22.8% does not match the reported count 59/266
“59 (22.8%)”
Safety - PERCENT7% does not match the reported count 18/264
“18 (7.0%)”
Safety - PERCENT12.6% does not match the reported count 33/264
“12.6%”
Safety - PERCENT15.6% does not match the reported count 41/266
“15.6%”
Safety
- CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Primary endpoint: baxdrostat 1 mg vs placebo, LS mean difference -8.7 mmHg (95% CI -11.5 to -5.8), P<0.0001
“Estimated treatment differences of baxdrostat 1 mg and 2 mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001), respectively.”
Taken as given: The CI is a 95% confidence interval for the difference in means.; The estimate is the difference in LS means.; The p-value is two-sided.Method: Recomputed p-value from the estimate and 95% CI using the normal approximation for the difference in means.How we recomputed it: pCI(-8.7, -11.5, -5.8, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Primary endpoint: baxdrostat 2 mg vs placebo, LS mean difference -9.8 mmHg (95% CI -12.6 to -7.0), P<0.0001
“Estimated treatment differences of baxdrostat 1 mg and 2 mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001), respectively.”
Taken as given: The CI is a 95% confidence interval for the difference in means.; The estimate is the difference in LS means.; The p-value is two-sided.Method: Recomputed p-value from the estimate and 95% CI using the normal approximation for the difference in means.How we recomputed it: pCI(-9.8, -12.6, -7.0, 0) - CONSISTENTreported p = .002 · recomputed p = .002Reviewers 1, 2Secondary endpoint: randomized withdrawal, baxdrostat 2 mg vs placebo, LS mean difference -5.1 mmHg (95% CI -8.3 to -1.9), P=0.0016
“The change in LS mean seated-SBP during the randomized withdrawal period was –3.7 mmHg (95% CI, –5.5 to –1.9) with baxdrostat 2 mg and +1.4 mmHg (95% CI, –1.2 to 4.0) with placebo (estimated difference of –5.1 mmHg [95% CI, –8.3 to –1.9; P=0.0016])”
Taken as given: The CI is a 95% confidence interval for the difference in means.; The estimate is the difference in LS means.; The p-value is two-sided.Method: Recomputed p-value from the estimate and 95% CI using the normal approximation for the difference in means.How we recomputed it: pCI(-5.1, -8.3, -1.9, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Secondary endpoint: resistant hypertension subpopulation, baxdrostat 1 mg vs placebo, LS mean difference -9.1 mmHg (95% CI -12.6 to -5.7), P<0.0001
“In the resistant hypertension subpopulation, LS mean estimated placebo-corrected treatment differences in seated-SBP change at week 12 were –9.1 mmHg (95% CI, –12.6 to –5.7; P<0.0001) with baxdrostat 1 mg and –9.8 mmHg (95% CI, –13.1 to –6.4; P<0.0001) with baxdrostat 2 mg”
Taken as given: The CI is a 95% confidence interval for the difference in means.; The estimate is the difference in LS means.; The p-value is two-sided.Method: Recomputed p-value from the estimate and 95% CI using the normal approximation for the difference in means.How we recomputed it: pCI(-9.1, -12.6, -5.7, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Secondary endpoint: resistant hypertension subpopulation, baxdrostat 2 mg vs placebo, LS mean difference -9.8 mmHg (95% CI -13.1 to -6.4), P<0.0001
“In the resistant hypertension subpopulation, LS mean estimated placebo-corrected treatment differences in seated-SBP change at week 12 were –9.1 mmHg (95% CI, –12.6 to –5.7; P<0.0001) with baxdrostat 1 mg and –9.8 mmHg (95% CI, –13.1 to –6.4; P<0.0001) with baxdrostat 2 mg”
Taken as given: The CI is a 95% confidence interval for the difference in means.; The estimate is the difference in LS means.; The p-value is two-sided.Method: Recomputed p-value from the estimate and 95% CI using the normal approximation for the difference in means.How we recomputed it: pCI(-9.8, -13.1, -6.4, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Secondary endpoint: seated-DBP, baxdrostat 1 mg vs placebo, LS mean difference -3.3 mmHg (95% CI -5.2 to -1.4), P=0.0008
“For seated-DBP, LS mean estimated placebo-corrected treatment differences at week 12 were –3.3 mmHg (95% CI, –5.2 to –1.4; P=0.0008) with baxdrostat 1 mg and –3.9 mmHg (95% CI, –5.7 to –2.0; P<0.0001) with baxdrostat 2 mg”
Taken as given: The CI is a 95% confidence interval for the difference in means.; The estimate is the difference in LS means.; The p-value is two-sided.Method: Recomputed p-value from the estimate and 95% CI using the normal approximation for the difference in means.How we recomputed it: pCI(-3.3, -5.2, -1.4, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Secondary endpoint: seated-DBP, baxdrostat 2 mg vs placebo, LS mean difference -3.9 mmHg (95% CI -5.7 to -2.0), P<0.0001
“For seated-DBP, LS mean estimated placebo-corrected treatment differences at week 12 were –3.3 mmHg (95% CI, –5.2 to –1.4; P=0.0008) with baxdrostat 1 mg and –3.9 mmHg (95% CI, –5.7 to –2.0; P<0.0001) with baxdrostat 2 mg”
Taken as given: The CI is a 95% confidence interval for the difference in means.; The estimate is the difference in LS means.; The p-value is two-sided.Method: Recomputed p-value from the estimate and 95% CI using the normal approximation for the difference in means.How we recomputed it: pCI(-3.9, -5.7, -2.0, 0)
- lowinternal contradictionIn Table 3, the number of participants with potassium >6.0 mmol/l is reported as 6 (2.3%) for baxdrostat 1 mg, but in the text it says 'Serum potassium levels >6 mmol/l were recorded in a central laboratory for 6 (2.3%), 8 (3.0%) and 1 (0.4%) participants receiving baxdrostat 1 mg, baxdrostat 2 mg and placebo, respectively.' This is consistent, but the table footnote says 'One case of hyperkalaemia (baxdrostat 1 mg) and two cases of hyponatremia (baxdrostat 1 mg and 2 mg) were deemed by investigators to be possibly related to baxdrostat.' This is not a contradiction.
Table 3: '>6.0 mmol/l | 1/262 (0.4) | 6/262 (2.3) | 8/263 (3.0)'
Table 3reviewer’s wording - lowinternal contradictionThe abstract states 794 participants were randomized and received treatment, but the results section says 796 were randomized and 794 received treatment. This is a minor discrepancy in the number randomized.
Abstract: '794 participants were randomized to and received baxdrostat 1mg (n=264), baxdrostat 2mg (n=266), or placebo (n=264)'; Results: '796 were randomized and 794 received treatment'
Abstractreviewer’s wording
Overstated conclusions
2 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Conclusions only partially backed by the presented evidenceAssessed
5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewer 1The slow offset of baxdrostat's effect on BP is consistent with its mechanism of action on sodium homeostasis.The paper speculates on the mechanism but does not provide direct evidence linking the slow offset to sodium homeostasis; it is a plausible hypothesis.Evidence: Discussion: 'We speculate that the slow offset of baxdrostat’s effect on BP is consistent with its mechanism of action on sodium homeostasis.'
“We speculate that the slow offset of baxdrostat’s effect on BP is consistent with its mechanism of action on sodium homeostasis.”
DiscussionFind in source - supportedReviewers 1, 2Baxdrostat added to background therapy resulted in a reduction in seated-SBP at 12 weeks compared with placebo in patients with uncontrolled or resistant hypertension.The primary endpoint showed statistically significant reductions in seated-SBP for both baxdrostat doses compared to placebo, with effect sizes and confidence intervals reported.Evidence: Primary endpoint results: LS mean differences of -8.7 mmHg (95% CI -11.5 to -5.8; P<0.0001) for 1 mg and -9.8 mmHg (95% CI -12.6 to -7.0; P<0.0001) for 2 mg vs placebo.
“Baxdrostat added to background therapy resulted in a reduction in seated-SBP at 12 weeks compared with placebo in patients with uncontrolled or resistant hypertension.”
ConclusionFind in source - supportedReviewers 1, 2The BP lowering effects of baxdrostat were consistent with those reported for the aldosterone synthase inhibitor lorundrostat.The paper cites a phase 3 trial of lorundrostat with a similar placebo-adjusted reduction in office SBP, supporting the claim of consistency.Evidence: Discussion: 'In a phase 3 trial in patients with uncontrolled and resistant hypertension, the placebo-adjusted reduction in office SBP with lorundrostat 50 mg was –9.1 mmHg (95% CI, –13.3 to –4.9) at week 6 (primary endpoint).'
“The BP lowering effects of baxdrostat in our study were consistent with those reported for the aldosterone synthase inhibitor lorundrostat.”
DiscussionFind in source - supportedReviewers 1, 2The mean change of –7.0 ml/min/1.73m2 in eGFR from baseline to week 12 observed in participants treated with baxdrostat occurred early, and during the randomized withdrawal period eGFR returned towards baseline levels in the placebo group.The paper reports eGFR changes and their recovery in the placebo group during withdrawal, supporting the claim.Evidence: Results: 'The mean change in estimated glomerular filtration rate (eGFR) from baseline to week 12 was –7.0 ml/min/1.73m2 (SD 12.8) and –6.9 (12.4) ml/min/1.73m2 in participants receiving baxdrostat 1 and 2 mg, respectively, and –0.1 (8.6) ml/min/1.73m2 in those receiving placebo.' and 'During the randomized withdrawal period (part 3), eGFR remained stable in the baxdrostat 2 mg group and returned towards baseline levels in the placebo group.'
The mean change of –7.0 ml/min/1.73m2 in eGFR from baseline to week 12 observed in participants treated with baxdrostat occurred early, and during the randomized withdrawal period (part 3), eGFR returned towards baseline levels in the placebo group.
Resultsreviewer’s wording - supportedReviewer 2Hyperkalemia and hyponatremia occurred more frequently in the baxdrostat groups versus placebo, but there was a low incidence of hyperkalemia leading to discontinuation and a low rate of potassium measurements >6.0 mmol/l.Safety data in Table 3 show higher rates of hyperkalemia and hyponatremia in baxdrostat groups, with low rates of discontinuation and potassium >6.0 mmol/l.Evidence: Table 3 shows hyperkalemia AESI in 7 (2.7%) and 21 (7.9%) for baxdrostat 1 mg and 2 mg vs 0 (0%) for placebo; potassium >6.0 mmol/l in 6 (2.3%) and 8 (3.0%) vs 1 (0.4%).
Hyperkalemia and hyponatremia occurred more frequently in the baxdrostat groups versus placebo, but there was a low incidence of hyperkalemia leading to discontinuation and a low rate of potassium measurements >6.0 mmol/l.
Resultsreviewer’s wording
Premise concern: surrogate not validated for clinical benefit.
- INADEQUATESurrogate endpointThe primary endpoint is change in seated systolic blood pressure (SBP), a surrogate for cardiovascular outcomes. The paper does not demonstrate target engagement at the tested doses (e.g., PK/PD or dose-exposure relationship) nor cite validated evidence linking SBP reduction to clinical outcomes in this context. Although SBP is a well-established surrogate for cardiovascular risk, the manuscript does not explicitly provide such validation or target engagement data.
“The primary efficacy end point was the change in seated-SBP, from baseline to week 12, assessed for each baxdrostat group versus placebo.”
- ADEQUATEEffect sizeThe treatment effect is a placebo-adjusted reduction in seated SBP of 8.7 mmHg (1 mg) and 9.8 mmHg (2 mg) at week 12. These are clinically meaningful reductions, as the discussion notes that '5–10 mmHg reductions in SBP are associated with reduced risk of cardiovascular disease and death.' The effect is statistically significant (P<0.0001) and anchored to clinical meaningfulness.
“Estimated treatment differences for baxdrostat 1mg and 2mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and – 9.8 mmHg (–12.6 to –7.0; P<0.0001), respectively.”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
The introduction cites prior work on aldosterone dysregulation, MRAs, and the phase 2 BrigHTN and HALO trials, acknowledging both positive and negative results. The rationale for testing baxdrostat is clearly derived from the need for an alternative to MRAs and the mixed results of prior trials. The paper does not explicitly describe how limitations of prior research are addressed, but the design of a larger phase 3 trial with a broader population implicitly addresses some limitations.
“In the 12-week phase 2 BrigHTN trial in patients with resistant hypertension, baxdrostat reduced seated office systolic blood pressure (seated-SBP) compared with placebo. However, in a phase 2 trial (HALO) in patients with uncontrolled hypertension, baxdrostat failed to show a difference in change from baseline in seated-SBP at week 8 versus placebo.”
“An alternative therapeutic approach is direct inhibition of aldosterone synthase, which catalyzes the final three steps in aldosterone biosynthesis.”
“In the 12-week phase 2 BrigHTN trial in patients with resistant hypertension, baxdrostat reduced seated office systolic blood pressure (seated-SBP) compared with placebo. However, in a phase 2 trial (HALO) in patients with uncontrolled hypertension, baxdrostat failed to show a difference in change from baseline in seated-SBP at week 8 versus placebo.”
“Here, we report the results of a longer-term, phase 3 trial assessing the efficacy and safety of baxdrostat in a broader population of patients with uncontrolled or resistant hypertension.”
The trial is described as randomized, double-blind, and placebo-controlled. Randomization was stratified by hypertension status and baseline SBP, but the specific method (e.g., random number generator) is not stated. Blinding is described as double-blind, and the open-label phases are clearly delineated. A power analysis is provided (720 participants for 98% power). Inclusion/exclusion criteria are summarized and referenced in the supplement. Outlier handling is addressed through pre-specified analysis populations and multiple imputation for missing data. The control group is placebo, and independent replication is not applicable for a single pivotal trial.
“Randomization was stratified by baseline hypertension status (uncontrolled hypertension, resistant hypertension) and baseline seated-SBP (<145, ≥145 mmHg).”
“This multinational, randomized, double-blind, placebo-controlled phase 3 trial”
“It was estimated that 720 participants would need to be randomized to achieve 98% power to detect a mean (standard deviation [SD]) difference of 6 (15) mmHg for change from baseline in seated-SBP at week 12 in favor of baxdrostat versus placebo using a two-sample t-test with a two-sided significance level of 0.025.”
“Participants were randomly assigned 1:1:1 to receive baxdrostat 1 mg, baxdrostat 2 mg, or placebo once daily. Randomization was stratified by baseline hypertension status (uncontrolled hypertension, resistant hypertension) and baseline seated-SBP (<145, ≥145 mmHg).”
“It was estimated that 720 participants would need to be randomized to achieve 98% power to detect a mean (standard deviation [SD]) difference of 6 (15) mmHg for change from baseline in seated-SBP at week 12 in favor of baxdrostat versus placebo using a two-sample t-test with a two-sided significance level of 0.025.”
Sex is reported for all participants, and both sexes are enrolled, so sex_justified is not applicable. Age, weight (via BMI), and health status (diabetes, eGFR) are reported. Demographics include age, sex, race/ethnicity, and comorbidities. Species/strain and housing conditions are not applicable for a human trial.
“Male sex – no. (%) | 162 (61.4) | 169 (64.0) | 163 (61.3)”
“Diabetes – no. (%) | 110 (41.7) | 83 (31.4) | 110 (41.4)”
“Age – yrs | 61.9±11.6 | 59.8±11.8 | 61.8±11.7 | | Male sex – no. (%) | 162 (61.4) | 169 (64.0) | 163 (61.3)”
The paper states that 'Institutional Review Boards/Independent Ethics Committees approved the protocol' and 'all participants provided written, informed consent before enrollment.' It also mentions compliance with the Declaration of Helsinki and ICH-GCP guidelines. This satisfies the requirements for human research.
“Institutional Review Boards/Independent Ethics Committees approved the protocol (available at nejm.org (https://nejm.org/) ), and all participants provided written, informed consent before enrollment.”
“the trial was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference for Harmonization Good Clinical Practice guidelines, and applicable laws and regulations.”
“Institutional Review Boards/Independent Ethics Committees approved the protocol (available at nejm.org (https://nejm.org/) ), and all participants provided written, informed consent before enrollment.”
“the trial was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference for Harmonization Good Clinical Practice guidelines, and applicable laws and regulations.”
Baxdrostat is identified as the investigational drug with doses (1 mg and 2 mg) and regimen (once daily). The statistical software (SAS) is identified. No antibodies, cell lines, or other bench reagents are used, so those criteria are not applicable.
“Participants were randomly assigned 1:1:1 to receive baxdrostat 1 mg, baxdrostat 2 mg, or placebo once daily.”
“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”
“randomized (1:1:1) to baxdrostat 1mg, baxdrostat 2mg, or placebo once daily for 12 weeks.”
“All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC, USA).”
The primary analysis uses ANCOVA, which is named. Effect sizes are reported as LS mean differences with 95% CIs. P-values are reported as thresholds (e.g., P<0.0001) rather than exact values, which is common in large trials. Assumptions are handled by the pre-specified model. Data presentation includes forest plots and tables with per-group n. Mathematical plausibility is not applicable for large-N continuous outcomes.
“The primary analysis used analysis of covariance (ANCOVA) with treatment and hypertension status (uncontrolled, resistant) as factors and baseline seated-SBP as a covariate.”
“Estimated treatment differences of baxdrostat 1 mg and 2 mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001), respectively.”
“The primary analysis used analysis of covariance (ANCOVA) with treatment and hypertension status (uncontrolled, resistant) as factors and baseline seated-SBP as a covariate.”
“Estimated treatment differences of baxdrostat 1 mg and 2 mg relative to placebo were –8.7 mmHg (95% CI, –11.5 to –5.8; P<0.0001) and –9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001), respectively.”
There is no explicit data availability statement in the paper. The trial is registered on ClinicalTrials.gov, but that is not a data repository. No accession numbers or code sharing are mentioned. For a clinical trial, a data availability statement is required, and managed access is acceptable, but its absence is a reporting gap.
The trial is registered on ClinicalTrials.gov (NCT06034743). Methods are detailed enough for replication. Limitations are discussed (e.g., low number of ambulatory BP measurements, underrepresentation of women and Black participants). Conclusions are proportional to the results. Funding and COI are disclosed. No specific reporting guideline (e.g., CONSORT) is mentioned, but the paper follows standard clinical trial reporting.
“BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743)”
“The present study has certain limitations. Ambulatory BP was measured in only a small number of participants.”
“The BaxHTN trial was funded by AstraZeneca.”
“BaxHTN clinicaltrials.gov number, NCT06034743 (https://clinicaltrials.gov/ct2/show/NCT06034743)”
“The present study has certain limitations. Ambulatory BP was measured in only a small number of participants.”
Registered (2 IDs: ClinicalTrials.gov). No reporting guideline cited.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 25 references by DOI: 24 verified — 1 no DOI (shown, not verified).
- NO DOIBaxdrostat in patients with uncontrolled hypertensionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
2 data/code links checked; 2 live.
- datahttps://clinicaltrials.gov/ct2/show/NCT06034743LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/study/NCT06168409LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
6 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 6 minor suggestions below.
6 copyedit issues flagged: mostly consistency, typo.
- MINORtypoResults, Safety“Hyperkaemia (potassium levels >5.5mmol/l) occurred in 16/262 (6.1%), 29/261 (11.1%) and 1/260 (0.4)”→ Change 'Hyperkaemia' to 'Hyperkalemia' and add a closing parenthesis after '0.4'.Spelling inconsistency and missing parenthesis.
- MINORconsistencyResults, Safety“The percent change in eGFR >30% that occurred on treatment was 12.6%, 15.6% and 1.5% and, ≥30% was 12.6%, 15.6% and 1.5% and ≥50% in 0.4, 1.5 and 1.1%”→ Clarify the sentence to avoid repetition and ensure clarity.Repetitive and confusing phrasing.
- MINORconsistencyResults, Safety“Serum potassium levels >6 mmol/l were recorded in a central laboratory for 6 (2.3%), 8 (3.0%) and 1 (0.4%) participants receiving baxdrostat 1 mg, baxdrostat 2 mg and placebo, respectively (, ).”→ Ensure the order of groups matches the order of numbers consistently.Order of groups in text may be inconsistent with table.
- MINORtypoAbstract, Results“Potassium >6.0 mmol/l occurred in 6 participants (2.3%) with baxdrostat 1mg, 8 (3.0%) with baxdrostat 2mg, and 1 (0.4%) with placebo.”→ Add a space between number and unit: '6 participants (2.3%)' is fine, but '1mg' should be '1 mg'.Inconsistent spacing of 'mg'.
- MINORconsistencyResults, Safety“Hyperkaemia (potassium levels >5.5mmol/l) occurred in 16/262 (6.1%), 29/261 (11.1%) and 1/260 (0.4)”→ Complete the sentence with a period and ensure consistent spelling of 'hyperkalemia'.Incomplete sentence and spelling inconsistency.
- MINORconsistencyResults, Safety“The percent change in eGFR >30% that occurred on treatment was 12.6%, 15.6% and 1.5% and, ≥30% was 12.6%, 15.6% and 1.5% and ≥50% in 0.4, 1.5 and 1.1%”→ Clarify the sentence structure and ensure consistent use of '>' and '≥'.Confusing repetition and inconsistent symbols.
The published work is methodologically robust and the conclusions are supported by the reported data. An informed reader should weigh the absence of a data availability statement and the minor discrepancy in the number randomized; these are reporting gaps that could warrant a correction or clarification, but they do not undermine the core findings.
- 1.CRITICALstatisticsCorrect or explain the statistically impossible value: PERCENT: 19.1% does not match the reported count 49/264Demonstrable critical failure — blocks the verdict from passing.
- 2.CRITICALstatisticsCorrect or explain the statistically impossible value: PERCENT: 22.8% does not match the reported count 59/266Demonstrable critical failure — blocks the verdict from passing.
- 3.HIGHdata codeAdd a data availability statement in the Methods or a dedicated section, specifying how de-identified participant data can be accessed (e.g., via a data-sharing platform or on reasonable request with a data access committee).The absence of a data availability statement is a reporting gap for a clinical trial and is required by most journals.
- 4.HIGHreportingReconcile the discrepancy in the number of participants randomized: the abstract states 794 were randomized and received treatment, while the results section says 796 were randomized and 794 received treatment.An internal contradiction in the number randomized could confuse readers and may warrant a correction.
- 5.MEDIUMcopyeditFix the typo 'Hyperkaemia' to 'Hyperkalemia' and add a closing parenthesis after '0.4' in the Results, Safety section.Spelling inconsistency and missing parenthesis are minor but should be corrected for professionalism.
- 6.MEDIUMcopyeditClarify the sentence in Results, Safety about percent change in eGFR to avoid repetition and ensure consistent use of '>' and '≥'.The current phrasing is repetitive and confusing, which could obscure the safety data.
- 7.MEDIUMcopyeditEnsure consistent spacing of 'mg' (e.g., '1mg' should be '1 mg') in the Abstract and Results.Inconsistent spacing is a minor formatting issue that should be standardized.
- 8.MEDIUMreportingMention adherence to a reporting guideline such as CONSORT in the Methods or a footnote.Explicitly referencing a reporting guideline enhances transparency and reproducibility.
- 9.MEDIUMstatisticsReport exact p-values (e.g., P=0.00003) instead of thresholds like P<0.0001 where possible.Exact p-values improve transparency and allow readers to assess the strength of evidence more precisely.
- 10.MEDIUMrigorProvide more detail on the randomization method (e.g., use of a central interactive response technology) in the Methods.Specifying the randomization method strengthens the reproducibility of the trial design.
- 11.MEDIUMdata codeConsider depositing the statistical analysis code (e.g., SAS programs) in a public repository to enhance reproducibility.Sharing analysis code allows independent verification of the statistical results.
- 12.LOWreportingState the manufacturer of baxdrostat explicitly in the Methods or acknowledgments.Identifying the manufacturer of the investigational product is standard practice for drug trials.
- 13.LOWreportingClarify how limitations of prior research (e.g., HALO trial failure) were addressed in the study design, perhaps in the Discussion.Explicitly addressing prior limitations strengthens the scientific premise.
- 14.LOWreportingInclude a statement on whether the study protocol and statistical analysis plan are publicly available.Public availability of the protocol and SAP enhances transparency and reproducibility.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.